Scandidos
1.67 SEK +0.6%Be the first to follow this company
Scandidos are active in medical technology. The company provides products and systems for quality assurance of advanced radiation therapy against cancer. The systems analyze the radiation dose before and during ongoing radiation treatment. The company was founded in 2002 and the first product was launched in 2006. Since its inception, Scandidos has delivered products to radiation therapy clinics on a global level. The head office is located in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SDOS
Daily low / high price
1.64 / 1.69
SEK
Market cap
95.21M SEK
Turnover
31.56K SEK
Volume
19K
Latest videos
Financial calendar
Interim report
18.09.2024
General meeting
23.10.2024
Interim report
17.12.2024
Interim report
12.03.2025
Annual report
18.06.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Spore Invest AB | 29.5 % | 29.5 % |
Commerzbank AG, W8IMY - IBA Dosimetry | 10.1 % | 10.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
ScandiDos receives orders worth €478 000 from China
ScandiDos AB changes Certified Adviser and liquidity provider to Carnegie Investment Bank AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
ScandiDos achieves EU Medical Device Regulation certification for the Delta4 Phantom+ product line
ScandiDos receives orders worth €290 000 from China
ScandiDos and IBA Dosimetry deepen strategic alliance!
ScandiDos receives an order worth €263 000 from China
![Scandidos, Capital Markets Day, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/2d00f0cf-eafa-44dd-9af9-0c8b89ea0584.png)